ReviewSmall science2026
Bridging the Gap: How Organ-on-a-Chip Technology Facilitates the Battle against Glioma.
Review in Small science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mimicking tumor hypoxia in a glioblastoma-on-a-chip.Materials today. Bio · 2026Article
- Organoids to Model Tumor Microenvironment in Progression of Pathogenesis and Treatment Resistance in Glioblastoma Multiforme.Brain sciences · 2026Review
- Modeling gliomas with organoids: reconstructing the human neural microenvironment for translational neuro-oncology.Frontiers in oncology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma, a highly aggressive brain tumor, presents significant challenges in understanding its complex pathophysiology and developing effective treatments. This review critically examines the current glioma modeling platforms, including 2D culture, 3D cultures, glioma-on-a-chip (GoC) models, and animal models, with a focus on their applications in recapitulating the tumor microenvironment and evaluating treatment effectiveness. Particular attention is given to microfluidic GoC models, which offer unique capabilities to mimic the pathophysiological complexity of glioblastoma, including its interactions with the blood-brain barrier (BBB) and tumor vascularization. Recent advancements in these models are explored, highlighting their potential for clinical translation through improved understanding of drug permeability on the central nervous system, tumor progress, and therapeutic responses. In the end, the review discusses the clinical perspective of GoC applications and establishes key criteria for designing robust and clinically relevant glioma models. By addressing these challenges and highlighting future opportunities, the critical role of GoC platforms in bridging the gap between preclinical research and clinical outcomes is emphasized, offering a promising approach for more personalized and effective glioma therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.